37.Samsung Biologics vs Celltrion: CDMO vs Biosimilars, Q2 2026 Earnings and What Investors Should Watch
For Samsung Biologics, the central question is whether contracted customer demand can fill an expanding manufacturing network and generate attractive returns on new capacity.
For Celltrion, the central question is whether new products can move from regulatory approval to payer access, prescriptions, market share, profitable product mix and ultimately cash flow.
Why These Two Korean Biopharma Companies Need Different Frameworks
Samsung Biologics Co., Ltd. (KRX: 207940) and Celltrion, Inc. (KRX: 068270) operate in the same broad biopharmaceutical industry. Both manufacture biologic medicines at scale, both serve global markets, and both are exposed to the long-term growth of biologic therapies.
But those similarities do not mean their earnings engines are alike.
Following its Samsung Bioepis-related spin-off in 2025, Samsung Biologics positioned itself as a pure-play contract development and manufacturing organization, or CDMO. Customers bring development or manufacturing programs, while Samsung Biologics supplies technical capabilities, manufacturing infrastructure, regulatory-quality execution and production capacity.
Celltrion sits further downstream in the value chain. It develops and manufactures its own products, including biosimilars, and then has to commercialize them. That adds another layer of economic risk: a medicine can be approved by regulators and still take time to obtain reimbursement, win formulary access, gain physician adoption and generate meaningful prescriptions.
Contracted Manufacturing Model
The core variables are contract awards, customer program transfers, manufacturing execution, capacity utilization, plant ramp-up, operating leverage and returns on invested manufacturing capital.
Product Commercialization Model
The core variables are regulatory approvals, reimbursement, prescriptions, market share, pricing, product mix, cost of sales, inventory, receivables and cash conversion.
That is the basic reason a single “Korean biotech valuation framework” does not work particularly well for these two companies.
Samsung Biologics: The Earnings Chain Starts With the Customer Contract
For Samsung Biologics, the economic chain begins before a commercial batch is produced.
A customer program first has to be won. It then needs to move through technical transfer and manufacturing preparation before production can contribute meaningfully to revenue. As more programs move through the network, fixed manufacturing assets can be utilized more efficiently.
That makes contract visibility an important part of the Samsung Biologics investment case. But investors need to be precise about the terminology.
In its English Q2 2026 results release dated July 23, Samsung Biologics reported USD 21.6 billion of cumulative contract value. That number is useful as evidence of the scale of customer relationships accumulated over time, but it should not be described as current backlog.
A cumulative figure includes contract value accumulated over time. Backlog normally refers to remaining contracted work that has not yet been recognized as revenue. Without a company-defined backlog figure, investors should not treat the USD 21.6 billion number as future revenue waiting to be recognized.
The distinction matters because investors can otherwise overstate revenue visibility. A large historical contract total certainly demonstrates customer traction, but the more relevant forward-looking questions are how many programs remain in production, how quickly new programs move through technology transfer, and whether future contract wins are sufficient to utilize incremental capacity.
Why Capacity Is So Important for Samsung Biologics
Samsung Biologics reported 845,000 liters of global drug-substance manufacturing capacity. Its manufacturing network includes its large Songdo complex in Korea and a 60,000-liter Rockville, Maryland facility acquired in 2026, giving the company its first U.S. manufacturing presence.
The headline capacity number is impressive, but capacity itself is not an earnings metric.
A manufacturing plant has to be filled with customer programs. Those programs require technical transfer, validation, quality processes and commercial execution. New facilities also take time to ramp, and utilization during that ramp can materially affect margins and returns on capital.
This is why investors should think about Samsung Biologics in terms of contract demand relative to available capacity, rather than simply assuming that more liters automatically mean more revenue.
A useful utilization warning
Samsung Biologics provides a good example of why manufacturing KPIs need careful interpretation.
Management has described Plants 1 through 4 as operating at full utilization. Separately, the company's Q1 2026 regulatory filing disclosed a 70.6% batch-based utilization measure, calculated from 192 batches of production against 272 batches of capacity.
Those statements should not be treated as directly contradictory.
The plant scope, reporting period, denominator, maintenance schedule, changeovers and ramp-up assumptions can differ between management commentary and a regulatory filing. The correct conclusion is not that one number must be wrong. It is that investors need to understand the methodology before comparing utilization figures.
The same discipline is important when assessing future expansion. The analytical question is not simply “How much capacity does Samsung Biologics have?” It is “How efficiently can customer demand be converted into productive use of that capacity?”
Rockville Adds More Than Just 60,000 Liters
Samsung Biologics completed the acquisition of a 60,000-liter drug-substance manufacturing facility in Rockville, Maryland on March 31, 2026.
The importance of that facility is not limited to its contribution to global capacity.
It also gives Samsung Biologics a manufacturing presence inside the United States. Strategically, that can support closer proximity to U.S. customers, geographic diversification of manufacturing, additional supply-chain resilience and potentially easier onboarding of customer programs that prefer U.S.-based production.
Those advantages should still be treated as strategic possibilities rather than guaranteed revenue. A U.S. plant only creates economic value if customer programs fill it at acceptable margins and returns.
Celltrion: Approval Is the Beginning of the Commercial Process
Celltrion's earnings chain works differently.
A successful regulatory decision creates the right to sell a medicine. It does not guarantee commercial adoption.
A newly approved biosimilar still needs reimbursement, formulary placement, distribution coverage and physician acceptance. It then has to compete for prescriptions against the reference product and other biosimilars, often in markets where pricing and contracting are central to market-share gains.
That is why Celltrion investors need to follow a wider commercial dashboard than Samsung Biologics investors.
Prescription data can show whether physicians and patients are adopting a product. Market share can show whether that adoption is meaningful relative to competitors. Product mix can help explain changes in gross profitability. Inventories and receivables then help show whether commercial growth is translating efficiently into cash.
Celltrion's Q2 2026 Results Show Why Product Mix Matters
In Q2 2026, Celltrion reported revenue of KRW 1.3937 trillion and operating profit of KRW 451.8 billion, producing an operating margin of 32.4%.
The more important detail for understanding the earnings direction was the changing product mix.
Celltrion said revenue from new products increased 76% year over year and represented 65% of biologics revenue during the quarter. The company also reported a 38% cost-of-sales ratio, down 5.4 percentage points year over year and 2.1 percentage points sequentially.
That combination matters because a product company can grow revenue without necessarily improving earnings quality. What investors want to see is growth accompanied by a product mix and cost structure that support stronger profitability.
In Celltrion's case, the Q2 numbers suggest that investors should watch not merely whether newer products are selling, but whether those products continue to become large enough to improve the economics of the overall portfolio.
Prescription growth is useful—but it is not revenue
Celltrion has also highlighted prescription and market-share data for major products.
For example, the company reported that Zymfentra total prescriptions increased 185% year over year in Q1 2026. The timing is important: this is a Q1 prescription-growth figure, not a Q2 figure.
According to Celltrion, Remsima SC also exceeded 32% market share across the EU5. The company has described Yuflyma as holding a leading position in the European adalimumab market.
These figures are useful indicators of commercial traction, but they are company-reported market data. Unless the underlying third-party dataset is separately sourced, they should be attributed to Celltrion rather than presented as independently verified market statistics.
More importantly, neither prescriptions nor market share should be confused with revenue itself.
Revenue depends on factors including pricing, rebates, payer mix, contracting terms, distribution and timing. Strong prescription growth is encouraging only if it ultimately produces attractive revenue, margin and cash-flow economics.
Q2 2026: Similar Revenue, Different Earnings Meaning
| Q2 2026 | Samsung Biologics | Celltrion |
|---|---|---|
| Revenue | KRW 1.3209tn | KRW 1.3937tn |
| Operating profit | KRW 586.4bn | KRW 451.8bn |
| Operating margin | 44.4% | 32.4% |
| Primary earnings question | Are customer programs filling manufacturing capacity efficiently? | Are products converting approvals into profitable commercial sales? |
At first glance, the comparison seems simple. Celltrion generated slightly higher revenue, while Samsung Biologics produced higher operating profit and a materially higher operating margin.
It would be a mistake, however, to conclude from the margin difference alone that Samsung Biologics has the structurally superior business model.
The companies absorb risk at different points in the pharmaceutical value chain.
Samsung Biologics generally does not need to create prescription demand for the medicines it manufactures for customers. Its principal risks lie in winning programs, executing technology transfers, maintaining regulatory quality, operating plants efficiently and earning adequate returns on expensive manufacturing infrastructure.
Celltrion carries more of the commercial risk associated with its own products. R&D, regulatory approval, reimbursement, pricing, market access, sales execution and working capital can all affect the eventual economics.
A higher CDMO operating margin and a lower product-commercialization margin therefore do not represent identical risk-adjusted economics.
Why 845,000 Liters and 316,000 Liters Are Not an Apples-to-Apples Comparison
| Manufacturing Capacity | Samsung Biologics | Celltrion |
|---|---|---|
| Current global DS capacity | 845,000 L | 316,000 L |
| Future capacity | Additional network expansion remains part of the growth strategy | Approximately 571,000 L under the latest announced expansion plan |
| Primary economic use | Manufacturing programs for external customers | Own-product manufacturing plus growing third-party CMO activity |
| Main investor question | Can contract demand absorb capacity? | Can manufacturing support profitable commercialization and third-party demand? |
Celltrion's current drug-substance capacity is approximately 316,000 liters. Under the company's March 2026 expansion plan, that figure could rise to approximately 571,000 liters.
The distinction between current and planned capacity is essential. The 571,000-liter figure is a corporate plan, not installed capacity today.
More importantly, the liters represent different economic models.
Samsung Biologics primarily builds manufacturing infrastructure so external customer programs can use it. Celltrion's manufacturing network primarily supports its own commercial portfolio, although third-party contract manufacturing is becoming more significant.
This is why simply ranking the companies by total liters would tell investors very little about future earnings.
Celltrion's CMO Expansion Complicates—but Does Not Erase—the Difference
Celltrion is no longer purely an own-product manufacturing story.
The company has been building a third-party contract manufacturing business as an additional earnings pillar. Its announced agreements include a KRW 678.7 billion arrangement linked to its Branchburg facility and another global pharmaceutical supply agreement announced in March 2026 with a fixed value of KRW 294.9 billion, potentially increasing to KRW 375.4 billion.
Those contracts matter because they can diversify the utilization of Celltrion's manufacturing assets and introduce some CDMO-like economics into the business.
But they do not make Celltrion economically equivalent to Samsung Biologics.
Celltrion still depends heavily on the success of its own product portfolio. Its earnings therefore remain exposed to reimbursement, competitive pricing, prescription adoption, commercial inventory and other risks that are much less central to a pure-play CDMO model.
A better way to think about Celltrion's CMO strategy is as an additional growth and asset-utilization pillar—not as a replacement for its core biosimilar commercialization model.
Inventory Reveals Another Important Difference
The balance sheet offers another way to see the distinction between the companies.
Celltrion reported consolidated inventories of approximately KRW 2.864 trillion at March 31, 2026, up from approximately KRW 2.804 trillion at the end of 2025.
Large inventory balances are not automatically negative for a biopharmaceutical company. Inventory may be built ahead of launches, geographic expansion or expected commercial demand.
But inventory is still capital that has not yet turned into cash.
That creates a simple follow-up question for investors: are rising inventories being matched by prescription growth, product sales, receivable collection and ultimately operating cash flow?
This is particularly important during a period when Celltrion is expanding its newer product portfolio. Strong reported revenue is more convincing when the working-capital cycle also demonstrates that products are moving efficiently through the commercial system.
Operating Cash Flow: Useful, but Not a Scoreboard
In Q1 2026, Samsung Biologics reported approximately KRW 767.7 billion of cash flow from operating activities, while Celltrion reported approximately KRW 238.2 billion on a consolidated basis.
The difference is notable, but it should not be used to declare one model inherently superior.
Working-capital requirements differ significantly between a CDMO and a product-commercialization company. Celltrion has to manage inventories, receivables and the timing of product sales. Samsung Biologics has a different cash-flow cycle built around customer programs and manufacturing execution.
The more useful approach is to monitor each company's cash generation relative to its own business model.
For Samsung Biologics, investors should ask whether operating cash generation is sufficient to support large-scale capacity investment while maintaining attractive returns.
For Celltrion, investors should ask whether commercial growth is translating into stronger cash conversion rather than accumulating disproportionately in inventories or receivables.
Why the Same Valuation Framework Can Be Misleading
This business-model distinction becomes especially important when investors move from earnings analysis to valuation.
Samsung Biologics can reasonably be analyzed through a framework that emphasizes the durability of customer relationships, contract visibility, capacity utilization, manufacturing execution, operating leverage and returns on invested capital.
In conceptual terms, global CDMO companies such as Lonza can help international investors understand the type of economics involved: long customer programs, technical transfers, regulatory-quality execution, manufacturing utilization and long-term capacity planning.
That does not mean Samsung Biologics should simply be called “the Korean Lonza,” nor does it imply that their margins or valuations are directly comparable. The useful comparison is the structure of the business model, not a shortcut to a valuation multiple.
Celltrion requires a more product-specific framework.
Investors need to assess the maturity of each major product, the competitive environment, reimbursement, pricing, prescription growth, market share, product mix, cost of sales and the amount of working capital required to support commercial expansion.
In other words, Samsung Biologics is largely a question of contracted demand meeting manufacturing capacity. Celltrion is largely a question of product adoption meeting commercial economics.
That is why applying the same earnings multiple or interpreting the same margin level without adjusting for business-model risk can produce a misleading comparison.
Samsung Biologics' Next Expansion Question
Samsung Biologics is also pursuing expansion beyond its traditional large-molecule CDMO base.
In July 2026, the company announced an all-cash tender offer to acquire PolyPeptide, a peptide-focused CDMO, at CHF 44.31 per share, implying approximately CHF 1.46 billion of equity value.
The transaction had not been completed as of the research cutoff. Completion was expected toward the end of 2026 and remained subject to acceptance, regulatory approvals and other conditions.
If completed, the transaction could broaden Samsung Biologics' service portfolio into peptide manufacturing. But investors should treat that as a strategic scenario rather than a completed change to the company's current earnings base.
The same analytical discipline applies here as it does to plant capacity: strategic expansion only creates value if customer demand, execution and capital returns eventually support it.
What Could Challenge the Bull Case?
Samsung Biologics
- New contract awards could slow relative to manufacturing expansion.
- Technology transfer or customer onboarding could take longer than expected.
- New facilities could operate below optimal utilization during ramp-up.
- Large capital investments may produce lower returns if demand fails to absorb new capacity.
- Customer concentration and changes in major pharmaceutical outsourcing strategies remain relevant.
- The PolyPeptide transaction remains conditional until closing.
Celltrion
- Regulatory approval may not translate into rapid reimbursement or prescription adoption.
- Pricing pressure and biosimilar competition may limit the economics of market-share gains.
- Product mix may not improve margins as quickly as expected.
- Inventories and receivables may grow faster than cash conversion.
- Commercial investment and R&D requirements may remain significant.
- Third-party CMO growth may take time to become large enough to materially alter the earnings mix.
What Global Investors Should Watch Next
Samsung Biologics
- New CMO and CDO contract awards
- Technology-transfer progress for major customer programs
- Utilization and ramp-up of incremental manufacturing capacity
- Commercial use of the Rockville facility
- Operating cash generation relative to capital spending
- Progress and final closing status of the PolyPeptide transaction
Celltrion
- Prescription trends for newer products
- Reimbursement and formulary access in major markets
- New-product revenue mix
- Cost-of-sales and operating-margin progression
- Inventory and receivables relative to revenue growth
- Operating cash conversion
- Expansion of third-party CMO revenue
The Bottom Line
Samsung Biologics and Celltrion may both appear under the same broad Korean biotech label, but they should not be analyzed as interchangeable businesses.
Samsung Biologics primarily sells development and manufacturing services. Its earnings depend on winning customer programs, moving them successfully into production and keeping a growing manufacturing network economically productive.
Celltrion primarily sells medicines. Its economics depend on taking products beyond approval and converting them into payer access, prescriptions, profitable product sales and cash.
That difference explains why capacity means something different for each company, why operating margins are not directly comparable, why prescription growth matters much more for Celltrion, and why investors should not apply one valuation framework to both stocks simply because they operate in the same sector.
Samsung Biologics: Are new contracts and existing customer programs filling incremental capacity at attractive returns?
Celltrion: Are new products converting regulatory approvals into access, prescriptions, profitable sales and cash?
FAQ
Is Samsung Biologics a biosimilar company?
Samsung Biologics is primarily positioned as a pure-play CDMO following the Samsung Bioepis-related spin-off. Its core business is providing development and manufacturing services to biopharmaceutical customers.
Is Celltrion becoming a CDMO?
Celltrion is expanding third-party contract manufacturing, and that business could become a more meaningful growth pillar. However, its core economics still depend heavily on developing and commercializing its own biopharmaceutical products. It should not currently be analyzed as economically equivalent to a pure-play CDMO.
Why does manufacturing capacity matter more for Samsung Biologics?
Samsung Biologics invests heavily in manufacturing infrastructure that is intended to serve external customer programs. The key issue is whether those customer programs arrive quickly enough to support high utilization and attractive returns on the capital invested.
Why is prescription growth important for Celltrion?
Prescription growth helps show whether an approved medicine is gaining real-world commercial adoption. However, prescriptions are not the same as revenue because pricing, reimbursement, payer mix, rebates and distribution arrangements affect the amount of sales ultimately recognized.
Why should investors watch Celltrion's inventory?
Product companies often build inventory in advance of launches or expected demand. The balance itself is therefore not automatically negative. The key question is whether inventory converts efficiently into sales, receivables and operating cash flow.
Does Samsung Biologics' higher Q2 2026 margin mean it has the better business model?
Not necessarily. The two companies bear different types of risk and cost at different stages of the biopharmaceutical value chain. A direct comparison of operating margins without considering those structural differences can be misleading.
Sources
- Samsung Biologics — Q2 2026 Financial Results, July 23, 2026
- Samsung Biologics — Rockville Manufacturing Facility Acquisition Completion, March 31, 2026
- Samsung Biologics — PolyPeptide Tender Offer Announcement, July 20, 2026
- Samsung Biologics — Company Fact Sheet
- Celltrion — Q2 2026 Financial Results
- Samsung Biologics Q1 2026 regulatory filing, May 15, 2026.
- Celltrion Q1 2026 regulatory filing, May 15, 2026.
- Celltrion manufacturing-capacity expansion announcement, March 24, 2026.
- Celltrion third-party CMO agreement announcement, March 17, 2026.
- Celltrion Zymfentra prescription update, May 8, 2026.
댓글
댓글 쓰기